Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment

Trial Profile

Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2018

At a glance

  • Drugs Evacetrapib (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Dyslipidaemias
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Feb 2016 Results of this other trial (see profile 231542) published in the European Journal of Clinical Pharmacology
    • 10 Oct 2013 Planned End Date changed from 1 Dec 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov record.
    • 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top